Decision Immediately Expands Access to Heart Failure Therapy with National Coverage for More Than 66 Million[1] Patients
MARLTON, N.J., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Impulse Dynamics®, a global medical device company committed to improving the lives of people with heart failure (HF), announced today that the Centers for Medicare and Medicaid Services (CMS) issued a National Coverage Determination (NCD) for CCM® therapy. CCM® therapy for heart failure (HF) patients is one of only five therapies selected for the Transitional Coverage for Emerging Technologies (TCET) pathway in 2025. This determination marks a transformative milestone for HF patients and their providers, validating that CCM® therapy is no longer experimental or investigational.
“Today's decision represents a victory to HF patients and families who deserve timely access to life-changing, innovative therapies that allow patients to live life to the fullest,” said Jason Spees, CEO, Impulse Dynamics®. “We are grateful to CMS and to the American College of Cardiology, the Heart Failure Society of America, and the Heart Rhythm Society for their support and partnership in advancing access. This decision recognizes the evidence-based outcomes of CCM® therapy, with real-world use surpassing more than 12,000 patients to date and opens the pathway to greater care for HF patients.”
“This NCD is a turning point for patients and providers as it eliminates a major barrier to access by ensuring coverage and reimbursement for a significant population of patients,” said Dr. Kenneth Ellenbogen, MD, FHRS, Kimberling Professor of Cardiology at the Virginia Commonwealth University School of Medicine. “This ensures the reimbursement process becomes more straightforward, enabling physicians to confidently offer CCM® therapy to address symptoms and improve quality of life for HF patients.”
“CCM® is an evidence-backed therapy that has already demonstrated meaningful benefits for HF patients,” said Dr. Andrew Sauer, MD, Advanced Heart Failure & Transplant Cardiologist and Co-Director of the Cardiovascular Research and Clinical Scholars Program at Saint Luke's Mid America Heart Institute. “We are pleased to see CMS's support with this determination, which recognizes the potential of CCM® to help a sizable-population of eligible patients who face significant clinical challenges that come with HF.”
About the Optimizer® System and CCM® Therapy
The Optimizer® system delivers CCM® therapy — the company's proprietary technology — to the heart, providing clinically meaningful improvement to quality of life for appropriate HF patients. CCM® therapy is designed to significantly improve heart contraction, allowing more oxygen-rich blood to be pushed out through the body[2]. CCM® therapy is indicated to improve six-minute hall walk, quality of life, and functional status of NYHA Class III HF patients who remain symptomatic despite guideline directed medical therapy, are not receiving CRT, and have a left ventricular ejection fraction ranging from 25 to 45 percent. Impulse Dynamics® has completed numerous clinical studies, including several randomized controlled trials, the results of which appeared in more than 100 publications in leading medical journals.
About Impulse Dynamics®
Impulse Dynamics® is dedicated to advancing the treatment of HF for patients and the healthcare providers who care for them. The company pioneered its proprietary CCM® therapy, which uses the Optimizer® technology platform, to improve quality of life in HF patients. CCM® therapy is delivered through the Optimizer® system and approved for commercial use in the United States and countries worldwide. More than 12,000 patients have received the therapy as part of clinical trials and real-world use, where it is shown to be safe and effective for HF patients with debilitating symptoms who otherwise have few effective options available to them.
Contact:
Hilary Schilmbach
Impulse Dynamics
856-642-9933
hschlimbach@impulsedynamics.com
Rohan More
Impulse Dynamics
856-642-9933
rmore@impulsedynamics.com
随机文章
热门文章

V1.0重磅发布!四维天穹绘构低空天路
Merck Appoints David Weinreich as New Global Head of R&D and Chief Medical Officer for Healthcar
“兴火·燎原”总冠军诞生,云宏信息《金融高算力轻量云平台》登顶
泳池过滤器怎么选?揭开Waternics水武仕珍珠岩过滤器的“硬核密码”!
Graco推出QUANTM电动双隔膜泵系列的改进产品
2025上海CMEF:鱼跃以“AI+医疗”开启健康管理新纪元
再获殊荣!itc分布式综合管理平台荣获2024年度“分布式处理十大品牌”
北京爱育华医院耳鼻喉头颈外科高品质服务升级
交个朋友严选背后:为何是蛰伏三年的酃酃酒